What is the MECP2 gene and what is its role in Rett syndrome?

The MECP2 gene (pronounced "mek-pee-two") is an essential component of the human genetic code, carrying the instructions necessary to produce a protein known as "methyl-CpG binding protein 2" (MeCP2). This protein acts as a vital regulator or chemical "switch" within the body's cells, specifically in the brain, where it controls the activation or silencing of many other genes necessary for healthy neurodevelopment [1]. When a defect occurs in this gene, the effects extend to brain development and cognitive and motor functions.

How do MECP2 mutations lead to Rett syndrome?

Most cases of Rett syndrome occur as a result of a random mutation in the MECP2 gene, which is located on the X chromosome [2]. In girls, because they possess two X chromosomes, the healthy chromosome may act as a partial protective factor, allowing them to survive with symptoms of the disorder manifesting at varying levels of severity. In males, however, the absence of a second X chromosome to compensate for the mutation often makes the condition incompatible with life, leading to miscarriages, stillbirths, or very early death [2].

The presence of the genetic mutation does not necessarily mean identical symptoms across all cases. Scientists believe that the severity and variety of symptoms depend on the location of the mutation within the gene, how sex chromosomes interact, and the presence of other genes that may mitigate or exacerbate the effects resulting from MeCP2 protein dysfunction [1].

The impact of genetic defects on brain function

Inefficiency or a lack of the MeCP2 protein leads to dysfunction in mature brain cells, which explains the developmental changes observed in affected children. Although children develop normally in the first months of their lives (usually between 6 to 18 months), the mutation subsequently leads to a regression in acquired skills, such as loss of purposeful hand use, speech difficulties, and changes in breathing patterns and motor development [1] [2]. Researchers are currently striving to understand the molecular pathways affected by this defect in order to develop future treatments that can compensate for protein deficiency or manipulate biochemical pathways to halt the progression of the disorder [1].

Medical management and next steps

While there is no radical cure for Rett syndrome, there are therapeutic options aimed at improving quality of life and managing symptoms. In 2023, the drug "Trofinetide" was approved for use in children aged two years and older, as it works to reduce brain inflammation and increase protective proteins [1] [2]. For more details regarding general symptoms, you can review our article on Rett syndrome: Understanding the genetic neurodevelopmental disorder in girls (Arabic).

Parents are advised to monitor any behavioral or motor changes and consult a pediatric neurologist. Regarding breathing problems that may appear in the child, experts recommend remaining calm during episodes of irregular breathing (such as breath-holding or hyperventilation) as normal breathing patterns often return spontaneously [2]. However, one should always coordinate with the treating medical team to establish a periodic monitoring plan that includes evaluation of the spine, heart, and nutritional needs to ensure the best possible care for the child [1].

Medical references

• Rett Syndrome
• Rett syndrome